WE CLAIM:

~~1. A method of treating narcolepsy, excessive daytime sleepiness, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder comprising administering to a patient in need thereof, a therapeutically effective amount of a histamine-3 receptor inverse agonist, wherein the histamine-3 receptor inverse agonist is a compound, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.~~

~~2. The method as claimed in claim 1, wherein the pharmaceutically acceptable salts of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide are selected from hydrochloride salt, oxalate salt, succinate salt and tartrate salt.~~

~~3. The method as claimed in claim 1 and claim 2, wherein the pharmaceutically acceptable salt of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.~~

~~4. A method of treating narcolepsy as claimed in claim 1, comprising administering to a patient in need thereof, a therapeutically effective amount of a histamine-3 receptor inverse agonist is a compound, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.~~

~~5. A method of treating narcolepsy as claimed in claim 4, wherein the pharmaceutically acceptable salt is N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.~~

~~6. A method of treating as claimed in claim 4 and claim 5, wherein narcolepsy is narcolepsy associated with cataplexy.~~

~~7. A method of treating as claimed in claim 4 and claim 5, wherein narcolepsy is narcolepsy not associated with cataplexy.~~

8. A method of treating as claimed in claim 4 and claim 5, wherein narcolepsy is narcolepsy due to medical condition.

9. A method of treating excessive daytime sleepiness as claimed in claim 1, comprising administering to a patient in need thereof, a therapeutically effective amount of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

10. A method of treating excessive daytime sleepiness as claimed in claim 9, wherein the excessive daytime sleepiness is associated with narcolepsy, obstructive sleep apnea, restless leg syndrome, REM behavior disorder, posttraumatic stress disorder, autism, Down syndrome, periodic limb movements in sleep, menstrual-related hypersomnia or Kleine-Levin syndrome, comprising administering to a patient in need thereof, a therapeutically effective amount of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

11. A method of treating circadian rhythm sleep disorders as claimed in claim 1, comprising administering to a patient in need thereof, a therapeutically effective amount of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

12. A method of treating circadian rhythm sleep disorders as claimed in claim 11, wherein circadian rhythm sleep disorder is selected from irregular sleep-wake type, jet lag type or shift work type, comprising administering to a patient in need thereof, a therapeutically effective amount of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

13. A method of treating sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder as claimed in claim 1, comprising administering to a patient in need thereof, a therapeutically effective amount N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

14. A method of treating sleep and vigilance disorders associated with dementia as claimed in claim 1 and claim 13, wherein the dementia is selected from Lewy body dementia,

~~vascular dementia, senile dementia, dementia due to Alzheimer's disease, and dementia due to Parkinson's disease and/or Frontotemporal dementia.~~

~~15~~1. Use of a histamine-3 receptor inverse agonist, in the manufacture of a medicament for the treatment of narcolepsy, excessive daytime sleepiness, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder in a patient, wherein the histamine-3 receptor inverse agonist is a compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

~~16~~2. Use of histamine-3 receptor inverse agonist as claimed in claim ~~15~~1, wherein pharmaceutically acceptable salts of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide are selected from hydrochloride salt, oxalate salt, succinate salt and tartrate salt.

~~17~~3. Use of histamine-3 receptor inverse agonist as claimed in claim ~~15 and claim 16~~1 or 2, wherein the pharmaceutically acceptable salt of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

~~18~~4. Use of histamine-3 receptor inverse agonist as claimed in claim ~~15~~1, in the manufacture of a medicament for the treatment of narcolepsy, wherein the histamine-3 receptor inverse agonist is a compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

~~19~~5. Use of histamine-3 receptor inverse agonist as claimed in claim ~~18~~4, in the manufacture of a medicament for the treatment of narcolepsy, wherein the pharmaceutically acceptable salt of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

~~20~~6. Use of histamine-3 receptor inverse agonist as claimed in any one of claims 1 to 5~~18 and claim 19, in the manufacture of a medicament~~, wherein narcolepsy is narcolepsy associated with cataplexy.

~~21~~7. Use of histamine-3 receptor inverse agonist as claimed in any one of claims 1 to 5~~18 and claim 19, in the manufacture of a medicament~~, wherein narcolepsy is narcolepsy not associated with cataplexy.

~~22~~8. Use of histamine-3 receptor inverse agonist as claimed in any one of claims 1 to 5~~18 and claim 19, in the manufacture of a medicament~~, wherein narcolepsy is narcolepsy due to medical condition.

~~23~~9. Use of a histamine-3 receptor inverse agonist as claimed in any one of ~~the~~ claims 1 to 3~~15 to 17,~~ in the manufacture of a medicament for the treatment of excessive daytime sleepiness.

~~24~~10. Use of a histamine-3 receptor inverse agonist as claimed in claim ~~23~~9, wherein ~~manufacture of a~~the medicament is for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, restless leg syndrome, REM behavior disorder, posttraumatic stress disorder, autism, Down syndrome**,** periodic limb movements in sleep, menstrual-related hypersomnia or Kleine-Levin syndrome.

~~25~~11. Use of a histamine-3 receptor inverse agonist as claimed in any one of the claims 1 to 3~~15 to 17~~, wherein ~~manufacture of a~~the medicament is for the treatment of circadian rhythm sleep disorders.

~~26~~12. Use of a histamine-3 receptor inverse agonist as claimed in claim ~~25~~11~~, in manufacture of a medicament,~~ wherein circadian rhythm sleep disorder is selected from irregular sleep-wake type, jet lag type or shift work type.

~~27~~13. Use of a histamine-3 receptor inverse agonist as claimed in any one of the claims 1 to 3~~15 to 17~~, wherein ~~manufacture of a~~the medicament is for the treatment of sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder.

~~28~~14. Use of the histamine-3 receptor inverse agonist as claimed in claim ~~27~~13, wherein the dementia is selected from Lewy body dementia, senile dementia, ~~and~~ vascular

dementia, dementia due to Alzheimer's disease, dementia due to Parkinson's disease and/or Frontotemporal dementia.

~~29. Use of a histamine-3 receptor inverse agonist, for the treatment of narcolepsy, excessive daytime sleepiness, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder, wherein the histamine-3 receptor inverse agonist is a compound, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.~~

~~30. Use of histamine-3 receptor inverse agonist as claimed in claim 29, wherein pharmaceutically acceptable salts of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide are selected from hydrochloride salt, oxalate salt, succinate salt and tartrate salt.~~

~~31. Use of histamine-3 receptor inverse agonist as claimed in claims 29 and 30, wherein the pharmaceutically acceptable salt of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.~~

~~32. Use of histamine-3 receptor inverse agonist as claimed in any of the claims 29 to 31, for treatment of narcolepsy.~~

~~33. Use of histamine-3 receptor inverse agonist as claimed in claim 32, wherein the narcolepsy is narcolepsy associated with cataplexy.~~

~~34. Use of histamine-3 receptor inverse agonist as claimed in claim 32, wherein the narcolepsy is narcolepsy not associated with cataplexy.~~

~~35. Use of histamine-3 receptor inverse agonist as claimed in claim 32, wherein the narcolepsy is narcolepsy is due to medical condition.~~

~~36. Use of the histamine-3 receptor inverse agonist as claimed in any of the claims 29 to 31, for treatment of excessive daytime sleepiness.~~

~~37. Use of the histamine-3 receptor inverse agonist as claimed in claim 36, for treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, restless leg syndrome, REM behavior disorder, posttraumatic stress disorder, autism, Down syndrome, periodic limb movements in sleep, menstrual-related hypersomnia or Kleine-Levin syndrome.~~

~~38. Use of the histamine-3 receptor inverse agonist as claimed in any of the claims 29 to 31, for treatment of circadian rhythm sleep disorders.~~

~~39. Use of the histamine-3 receptor inverse agonist as claimed in the claim 38, wherein the circadian rhythm sleep disorder is selected from irregular sleep-wake type, jet lag type or shift work type.~~

~~40. Use of the histamine-3 receptor inverse agonist as claimed in any of the claims 29 to 31, for treatment of sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder.~~

~~41. Use of the histamine-3 receptor inverse agonist as claimed in claim 40, wherein the dementia is selected from Lewy body dementia, vascular dementia, senile dementia, dementia due to Alzheimer's disease, dementia due to Parkinson's disease and/or Frontotemporal dementia.~~

~~42~~15. Use of a~~A~~ pharmaceutical composition comprising N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof as claimed in any one of ~~the~~ claims 1 to ~~41~~ 3 and pharmaceutically acceptable excipients or combination thereof, in the manufacture of a medicament for ~~use in~~the treatment of narcolepsy, excessive daytime sleepiness, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder.

~~43~~16. The ~~pharmaceutical composition~~use as claimed in claim ~~42~~ 15, wherein the medicament is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

~~44~~17. The ~~pharmaceutical composition~~use as claimed in claim 15 or 16~~42 and claim 43~~, wherein the medicament is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.